Genprex

Category: Press Releases

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More


Genprex Issues April 2020 Shareholder Letter

Company provides updates on recent regulatory, clinical, operational, and business developments

Read More

Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations

Proven executive with clinical operations expertise to guide the Company’s clinical programs with gene therapies

Read More

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

These board additions will enhance the Company’s ability to execute on key corporate initiatives.

Read More

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.

Read More

Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview

Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Read More

Genprex to Present at the 2020 LD Micro Virtual Conference

Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Read More

Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants

The Company intends to use the net proceeds from the offering to advance its drug development programs and for working capital and general corporate purposes.

Read More

Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants

The closing of the registered direct offering is expected to take place on or about February 21, 2020, subject to the satisfaction of customary closing conditions.

Read More